BALCHEM CORP
No SEC Form 4 filings for $BCPC in the last 30 days.
See all $BCPC insider activity →Balchem (BCPC) announced a $0.3984 annual dividend per share, payable January 15 to shareholders of record on December 31. The company also outlined a $650M credit facility through 2031 and forecast a 22.5%-23% 2026 tax rate. BCPC reported strong Q2 results and is rated a buy by some analysts.
Balchem Corporation (BCPC) is scheduled to release its Q3'26 earnings on October 23. Analysts expect revenue of 289.25M USD and EPS of 1.43 USD. The results will be announced before the market opens at 9:30 AM ET.
Balchem (BCPC) reported Q2 2026 sales of $284 million and net income of $44.62 million, up from the prior year, and six-month sales of $554.71 million with net income of $84.9 million. The article cites improving EPS and profitability, discusses index inclusion, and references forecasts of $1.3 billion revenue and $196.2 million earnings by 2029.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BCPC (BALCHEM CORP). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent BCPC coverage spans earnings, corporate actions and financial news.
Dividend declaration may attract income-focused investors and support the stock price.
Pre‑earnings estimate may set market expectations and drive price action ahead of the release.
The article frames improving profitability from Q2 and year-to-date results as a potential shift in the bull case, but it provides no new guidance beyond the reported figures.
Balchem’s Q2 2026 earnings call said record results came from growth across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. ANH reported 15% sales growth and margin improvement, aided by encapsulated rumen-protected tech and EU antidumping duties. Management projected 2026 effective tax rate of 22.5% to 23%, repurchased about $29M of stock, and noted $650M credit capacity.
Q2 results show broad growth and strong cash generation, while the revolver amendment increases borrowing capacity and extends maturity, supporting liquidity for growth and acquisitions.
AlphAI scores every news story that mentions BCPC with an AI model for sentiment and relevance, and aggregates insider trades from BALCHEM CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Balchem (BCPC) announced a $0.3984 annual dividend per share, payable January 15 to shareholders of record on December 31. The company also outlined a $650M credit facility through 2031 and forecast a 22.5%-23% 2026 tax rate. BCPC reported strong Q2 results and is rated a buy by some analysts.
1 min readBalchem Corporation (BCPC) is scheduled to release its Q3'26 earnings on October 23. Analysts expect revenue of 289.25M USD and EPS of 1.43 USD. The results will be announced before the market opens at 9:30 AM ET.
1 min readBalchem (BCPC) reported Q2 2026 sales of $284 million and net income of $44.62 million, up from the prior year, and six-month sales of $554.71 million with net income of $84.9 million. The article cites improving EPS and profitability, discusses index inclusion, and references forecasts of $1.3 billion revenue and $196.2 million earnings by 2029.
6 min readBalchem’s Q2 2026 earnings call said record results came from growth across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. ANH reported 15% sales growth and margin improvement, aided by encapsulated rumen-protected tech and EU antidumping duties. Management projected 2026 effective tax rate of 22.5% to 23%, repurchased about $29M of stock, and noted $650M credit capacity.
7 min readBALCHEM CORP (BCPC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Human Nutrition & Health | Animal Nutrition & Health | Specialty Products Balchem Corporation Reports Second Quarter 2026 Financial Results Montvale, NJ, July 31, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal second qu
6 min readBALCHEM CORP (BCPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ef20078813_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 1 Dated as of July 24, 2026 to AMENDED AND RESTATED CREDIT AGREEMENT Dated as of July 27, 2022 THIS AMENDMENT NO. 1 (this “ Amendment ”) is made as of July 24, 2026 by and among Balchem Corporation (the “ Par
4 min readBALCHEM CORP (BCPC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000009326 0000009326 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 18, 2026
2 min readBalchem Corporation reported strong financial results for Q4 2025, exceeding EPS and revenue forecasts, which pushed their sales over $1 billion for the first time. Despite the positive earnings, the company's stock declined in pre-market trading, possibly due to profit-taking or high earnings multiples. Balchem highlighted strategic international expansion and continued investment in research and marketing through partnerships like those with the New York Jets and Bayern Munich women's soccer team, while maintaining a strong financial position with low leverage.
4 min readBalchem Corporation's stock has reached a new 52-week high of $177.41 USD, reflecting an 11.32% growth over the past year. The company has a strong record of financial stability, maintaining dividend payments for 40 consecutive years and raising them for 16 straight years. Recent developments include a 10.3% increase in its annual dividend and a "Neutral" rating with a $162.00 price target from Rothschild Redburn, highlighting its resilient business model.
2 min readMONTVALE, N.J., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Balchem Corporation ( NASDAQ:BCPC ) , a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird's 55th Annual Global Industrial Conference on November 12, 2025.
3 min read
